Gilead forecasts 2021 growth, strong remdesivir COVID-19 sales
(Reuters) - Gilead Sciences Inc on Thursday forecast its 2021 results above Wall Street estimates after posting a 26% rise in fourth-quarter 2020 revenue, driven by sales of its antiviral drug, remdesivir, which is used to treat COVID-19 patients.
